EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)

MSI-H/dMMR • BRAF mutation • HER-2 expression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type

Enhertu (fam-trastuzumab deruxtecan-nxki)

Mapping of DOG1 expression in colorectal carcinomas. (PubMed, Pathology)

DOG1-positive CAFs were associated with better overall survival. This study suggests that DOG1 expression is detected in a high proportion of CRC because it is expressed in neoplastic cells of various histological subtypes of CRC that secrete gel-forming mucins, independently of mucinous features or in CAFs of conventional adenocarcinomas.

2 days ago

Journal • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • KRT7 (Keratin-7) • CDX2 (Caudal Type Homeobox 2) • ANO1 (Anoctamin 1) • KRT20 (Keratin 20) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)

KRAS mutation • MSI-H/dMMR • BRAF mutation • RAS mutation

Prognostic and clinicopathologic significance of BRAF mutation in colon cancer by MSI status and stage: A large cohort analysis. (PubMed, Surg Oncol)

BRAF-mutated colon cancer demonstrates substantial biological and prognostic heterogeneity driven by MSI status and disease stage.

2 days ago

Journal

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)

BRAF mutation

C-IT Neo: CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (clinicaltrials.gov)

P2, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

2 days ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene)

BRAF mutation

Opdivo (nivolumab) • Yervoy (ipilimumab)

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (clinicaltrials.gov)

P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160

3 days ago

Enrollment change

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CLDN18 (Claudin 18) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • KRAS mutation • MSI-H/dMMR • HER-2 overexpression • BRAF mutation • HER-2 mutation • IDH1 mutation • CLDN18.2 expression • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion

Dual-targeted 68Ga-NOTA-3P-TATE-RGD PET/CT in Radioactive-iodine Negative Differentiated Thyroid Cancer: An Exploratory Comparative Study With 18F-FDG. (PubMed, Clin Nucl Med)

68Ga-NOTA-3P-TATE-RGD PET/CT is feasible for radioactive-iodine-negative DTC, providing complementary diagnostic information to 18F-FDG with enhanced detection of bone and brain metastases. The intense uptake observed in lesions with TERT-associated aggressive subtypes supports potential utility for specific disease identification.

4 days ago

Journal

BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase) • SSTR2 (Somatostatin Receptor 2)

BRAF mutation

Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry. (PubMed, JTO Clin Res Rep)

The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.

4 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion

Oncomine™ Dx Target Test

Computational phosphoproteomic insights into predominant BRAF phosphosites and associated regulatory networks in cancer. (PubMed, Biochim Biophys Acta Proteins Proteom)

These co-regulated proteins highlight the integration of BRAF signaling with critical processes, such as cell cycle control, apoptosis, DNA damage response, and protein synthesis in melanoma. Our analysis suggests that targeting BRAF-interacting proteins may also modulate oncogenic signaling pathways and represent promising biomarkers for melanoma diagnosis and therapy.

4 days ago

Journal

BRAF (B-raf proto-oncogene) • NPM1 (Nucleophosmin 1) • RB1 (RB Transcriptional Corepressor 1) • CHEK2 (Checkpoint kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD14 (CD14 Molecule) • CDK14 (Cyclin Dependent Kinase 14) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • EIF6 (Eukaryotic Translation Initiation Factor 6)

BRAF mutation

Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. (PubMed, Eur J Pharmacol)

FOXO1 carries both prognostic and predictive relevance in mRCC and independently predicts greater benefit from IO+TKI therapy. Integration of FOXO1 with complementary immune gene features into an RF-based model provides a promising framework for precision immunotherapy in advanced RCC.

5 days ago

Journal • IO biomarker

BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • BAP1 (BRCA1 Associated Protein 1) • CD4 (CD4 Molecule) • FOXO1 (Forkhead box O1)

BRAF mutation

Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses. (PubMed, Mediators Inflamm)

Our study reveals a myeloid-centered regulatory network in thyroid cancer and highlights TNFSF12 as a context-dependent oncogene, offering novel insights into targeted therapy and immunotherapeutic strategies.

6 days ago

Journal • IO biomarker

BRAF (B-raf proto-oncogene) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)

BRAF mutation

Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care. (PubMed, ESMO Real World Data Digit Oncol)

In a tumor-agnostic approach, biomarker-informed NSTT was associated with clinical benefit in 31.7% of the patients, with checkpoint inhibitors being the most common treatment. The INFINITY project demonstrates the feasibility of a large-scale precision oncology project in a community oncology setting and thus supports the implementation of precision oncology into routine clinical practice in Germany.

7 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)

BRAF mutation • HER-2 mutation • HER-2 expression

Expanding the Molecular Landscape of Deep Penetrating Nevus-like Melanomas Beyond CTNNB1 and APC Mutations: A Clinicopathologic and Molecular Study of 14 Cases. (PubMed, Am J Surg Pathol)

After a median follow-up of 33.5 months, 36% of patients developed distant metastases, and 2 patients died of disease 8 and 32 months, respectively, after initial diagnosis. These findings expand the molecular diversity of DPN-like melanomas and provide valuable insights into their clinical outcomes.

7 days ago

Journal • Tumor mutational burden

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ARID1A (AT-rich interaction domain 1A) • TERT (Telomerase Reverse Transcriptase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway) • FAT1 (FAT atypical cadherin 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

BRAF mutation